Get started
Author

Jorge Bartolomé

Observed names: J Bartolomé, J. Bartolomé, J. Bartolomé Arcilla, Jorge Bartolome, Jorge Bartolome Arcilla, Jorge Bartolomé Arcilla
ORCID: 0000-0002-2715-6529
Observed ORCID: 0000-0002-2715-6529
OpenAlex ID: A5102925404
Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients
2022 · Javier David Benitez Fuentes, Kauzar Mohamed Mohamed, et al. · Frontiers in Oncology · 33
Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis
2023 · Jorge Bartolome, Consolacion Molto, et al. · Frontiers in Immunology · 26
Targeting of Non-Classical Human Leukocyte Antigens as Novel Therapeutic Strategies in Cancer
2024 · Javier David Benitez Fuentes, Jorge Bartolome Arcilla, et al. · Cancers · 15
PDF
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
2024 · Piotr Jan Wysocki, Kyung Hae Jung, et al. · Journal of Clinical Oncology · 11
Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2
2024 · Lucía Paniagua-Herranz, Irene Moreno, et al. · International Journal of Molecular Sciences · 10
PDF
A snapshot of COVID ‐19 infection in patients with solid tumors
2020 · Jesús Fuentes‐Antrás, Aránzazu Manzano, et al. · International Journal of Cancer · 10
PDF
LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients
2024 · A.J. Montero, A. Giordano, et al. · Annals of Oncology · 9
PDF
Association between human leukocyte antigen E expression and outcomes in solid tumors: a systematic review and meta-analysis
2025 · Javier David Benitez Fuentes, Jorge Bartolome Arcilla, et al. · Frontiers in Oncology · 8
Understanding the Preclinical Efficacy of Antibody–Drug Conjugates
2024 · Cristina Díaz-Tejeiro, Alfonso López de Sá, et al. · International Journal of Molecular Sciences · 8
PDF
Abstract PS7-02: First-in-human results of STX-478, a mutant-selective PI3K alpha inhibitor, in HR+ breast cancer and advanced solid tumor patients
2025 · Dejan Juric, Antonio Giordano, et al. · Clinical Cancer Research · 5
Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma
2024 · Santiago Cabezas-Camarero, Rebeca Pérez-Alfayate, et al. · Neuro-Oncology Advances · 5
Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cells
2024 · Lucía Paniagua-Herranz, Cristina Díaz-Tejeiro, et al. · Frontiers in Immunology · 4
PDF
Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02 (DP-02).
2026 · Kyung Hae Jung, Do-Youn Oh, et al. · Journal of Clinical Oncology · 3
1029eTiP A phase I/II open-label study of NDI-219216, a WRN inhibitor, in patients with advanced solid tumors with or without microsatellite instability /deficient mismatch repair
2025 · J. Nemunaitis, A. Scheuber, et al. · Annals of Oncology · 3
PDF
Continuing cyclin-dependent kinase 4/6 inhibition in metastatic breast cancer patients previously treated with another cyclin-dependant kinase 4/6 inhibitor: a protocol for systematic review and meta-analysis
2022 · Alicia de Luna Aguilar, Javier David Benitez Fuentes, et al. · Research Square · 3
Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain
2022 · Javier David Benitez Fuentes, Alicia de Luna Aguilar, et al. · F1000Research · 3
PDF
Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trial
2025 · Sarina A Piha-Paul, Justin A Call, et al. · The Oncologist · 2
PDF
In silico evaluation of the immunogenic profile of lung cancers with SMARCA4 genetic alterations
2025 · Cristina Nieto-Jiménez, Esther Garcia-Lorenzo, et al. · Scientific Reports · 2
PDF
EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a phase 1/2 study EIK1003-001 in advanced solid tumors.
2026 · Martin Hojgaard, Jian Zhang, et al. · Journal of Clinical Oncology · 1
PDF
A phase 1/2 trial of tersolisib (LY4064809/STX-478), a pan-mutant-selective PI3Kα inhibitor (PI3Kαi), in PIK3CA -mutant advanced solid tumors: Updated results from PIKALO-1.
2026 · Komal L. Jhaveri, Alberto J. Montero, et al. · Journal of Clinical Oncology · 1
Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).
2024 · Sarina A. Piha-Paul, Justin A Call, et al. · Journal of Clinical Oncology · 1
PDF
Prognostic value of human leukocyte antigen G (HLA-G) expression in solid tumors: A systematic review and meta-analysis.
2023 · Jorge Bartolome, Consolacion Molto, et al. · Journal of Clinical Oncology · 1
PDF
1708P SMARCA4/SMARCB1 alterations detected through tissue comprehensive genomic profiling (CGP): A single-center study of prevalence and clinical characteristics
2022 · J. Bartolomé Arcilla, G. Fernandez-Hinojal, et al. · Annals of Oncology · 1
179P Clinical profile of SMARCA4/SMARCB1-mutated non-small cell lung carcinomas: A retrospective study in a Spanish institution
2022 · G. Fernandez, M. Antoñanzas-Basa, et al. · Annals of Oncology · 1
PDF
Tumor-type specific methylation patterns of MTAP in human samples and cell lines
2026 · Luis Álvarez-Carrión, Dalma Müller, et al. · Clinical Epigenetics
Works count: 38
Citation count: 166
H-index: 8
I10-index: 6
Year
Topic
Type